Danaher Reports Strong Q1 2026 Results and Acquisition Plans
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2024
0mins
Should l Buy DHR?
Source: Business Insider
Danaher Corp (DHR) experienced a price decline of 5.00%, hitting a 5-day low, despite the broader market's positive performance with the Nasdaq-100 up 1.44% and the S&P 500 up 0.81%.
The company's recent earnings report revealed a net income of $1.029 billion for Q1 2026, a 7.8% increase year-over-year, alongside an adjusted EPS of $2.06, exceeding expectations. Additionally, Danaher announced plans to acquire Masimo Corporation, enhancing its market position in acute care monitoring solutions. This acquisition is expected to leverage Danaher's global scale, further driving growth and shareholder value.
Despite the stock's decline, Danaher's strong earnings growth and acquisition strategy indicate a robust operational foundation, suggesting potential for recovery and long-term value creation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 178.570
Low
240.00
Averages
266.18
High
310.00
Current: 178.570
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Danaher Acquires Masimo for $9.9 Billion, Revitalizing Growth
- Blockbuster Acquisition: Danaher has acquired Masimo, a leader in pulse oximetry technology, for $9.9 billion, which is expected to add $530 million in EBITDA by 2027, enhancing its competitive edge in diagnostics.
- Financial Recovery: Danaher reported revenue growth mid-2024, with first-quarter non-GAAP earnings rising 9.5% year-over-year, exceeding Wall Street expectations and indicating a strong post-pandemic recovery.
- Attractive Valuation: Currently, Danaher trades at a price-to-earnings ratio of 22, significantly lower than its historical average of 32 over the past decade, suggesting that the stock is undervalued and may attract long-term investors.
- Future Growth Potential: Analysts project Danaher to grow earnings by 8% to 9% annually over the next three to five years, coupled with strong free cash flow and potential acquisition opportunities, indicating sustained competitiveness and growth potential in the industry.
See More
Danaher Acquires Masimo, Anticipates Future Growth
- Historical Performance Review: Since its founding in 1969, Danaher has achieved over 52,700% stock returns; however, following the COVID-19 pandemic, shares have dropped 36%, leading investors to question its future performance.
- Strategic Significance of Masimo Acquisition: Danaher is acquiring pulse oximetry leader Masimo for $9.9 billion, expected to add $530 million in EBITDA by 2027, thereby enhancing its competitive edge in the diagnostics sector.
- Financial Recovery Signs: Revenue began to rebound in mid-2024, with first-quarter non-GAAP earnings growing 9.5% year-over-year, surpassing Wall Street expectations, indicating the company's potential for market recovery.
- Future Growth Expectations: Analysts project Danaher to grow earnings by 8% to 9% annually over the next three to five years, and with a current P/E ratio of 22, the stock appears attractive for long-term investment.
See More
Danaher Corporation Settles $172.5M Class Action Lawsuit
- Settlement Amount Confirmed: Danaher Corporation has agreed to pay $172.5 million to settle a class action lawsuit from investors who accused the company of misrepresenting demand for its testing and vaccine equipment as the COVID-19 pandemic waned, indicating a significant financial burden in managing legal risks.
- Lawsuit Background: Investors alleged that Danaher issued false and misleading statements regarding its bioprocessing business in 2022 and 2023, claiming sustainable demand for its products, which led to multiple declines in stock price, reflecting the company's missteps in market communication.
- Court Proceedings Update: The settlement agreement was filed with the US District Court for the District of Columbia on Wednesday, and if approved, it will become the largest securities class action settlement handled by that court since the relevant law took effect in 1996, highlighting the case's broad implications.
- Company's Position: While agreeing to the settlement, Danaher denied any wrongdoing, stating that this move will allow the company to avoid burdensome litigation and stay focused on addressing the world's most critical health challenges, reflecting its strategic emphasis on future business development.
See More
Thermo Fisher Exceeds Q1 Profit and Revenue Estimates
- Performance Beat: Thermo Fisher reported Q1 revenue of $11.01 billion, surpassing analysts' expectations of $10.85 billion, reflecting a 6% year-over-year growth driven by strong laboratory products and biopharma services.
- Segment Performance: Revenue from laboratory products and biopharma services rose approximately 7% to $6.04 billion, while analytical instruments remained flat at $1.72 billion, and specialty diagnostics saw a slight decline of 0.5% to $1.14 billion, indicating diverse market demand.
- Market Challenges: Despite strong overall performance, Thermo Fisher faces challenges from reduced funding for universities and research institutions under the Trump administration, which may impact future growth as smaller biotech firms remain cautious post-pandemic.
- Profitability Improvement: The company reported adjusted earnings per share of $5.44, exceeding the analysts' estimate of $5.24, indicating improvements in cost control and operational efficiency, which bolsters investor confidence.
See More
Danaher Corporation Prices €2.98 Billion Senior Notes Offering
- Financing Scale: Danaher Corporation's offering of senior notes is expected to yield approximately €2.98 billion in net proceeds after deducting underwriting discounts and estimated offering expenses, demonstrating the company's robust capital market capabilities.
- Use of Proceeds: The company intends to allocate a portion of the net proceeds to pay for the cash consideration and associated costs of acquiring Masimo Corporation, a strategic acquisition that will enhance Danaher's market position in the medical technology sector.
- Issuance Timeline: The offering is expected to close on April 29, 2026, subject to customary closing conditions, indicating the company's efficiency and planning in capital operations.
- Compliance Statement: The notes are not intended for retail investors, adhering to relevant EU and UK regulations, ensuring compliance throughout the issuance process and targeting professional investors.
See More
Danaher Corporation Prices Euro-Denominated Senior Notes Offering
- Offering Size: Danaher Corporation announced a total offering of €3 billion in senior notes, including €500 million of floating rate notes and €1 billion of 4% fixed rate notes, demonstrating the company's strong financing capability in the capital markets.
- Use of Proceeds: The estimated net proceeds of approximately €2.98 billion will primarily fund the cash consideration for the acquisition of Masimo Corporation and associated costs, indicating a proactive strategy to expand business and enhance market competitiveness.
- Market Response: The notes were priced close to par, reflecting investor confidence in Danaher's financial health, while also laying a solid foundation for future capital operations.
- Compliance Statement: The offering adheres to SEC registration statements, ensuring compliance with relevant laws and regulations, which underscores the company's commitment to compliance and transparency, thereby enhancing investor trust.
See More
Danaher Acquires Masimo for $9.9 Billion, Revitalizing Growth
- Blockbuster Acquisition: Danaher has acquired Masimo, a leader in pulse oximetry technology, for $9.9 billion, which is expected to add $530 million in EBITDA by 2027, enhancing its competitive edge in diagnostics.
- Financial Recovery: Danaher reported revenue growth mid-2024, with first-quarter non-GAAP earnings rising 9.5% year-over-year, exceeding Wall Street expectations and indicating a strong post-pandemic recovery.
- Attractive Valuation: Currently, Danaher trades at a price-to-earnings ratio of 22, significantly lower than its historical average of 32 over the past decade, suggesting that the stock is undervalued and may attract long-term investors.
- Future Growth Potential: Analysts project Danaher to grow earnings by 8% to 9% annually over the next three to five years, coupled with strong free cash flow and potential acquisition opportunities, indicating sustained competitiveness and growth potential in the industry.
See More
Danaher Acquires Masimo, Anticipates Future Growth
- Historical Performance Review: Since its founding in 1969, Danaher has achieved over 52,700% stock returns; however, following the COVID-19 pandemic, shares have dropped 36%, leading investors to question its future performance.
- Strategic Significance of Masimo Acquisition: Danaher is acquiring pulse oximetry leader Masimo for $9.9 billion, expected to add $530 million in EBITDA by 2027, thereby enhancing its competitive edge in the diagnostics sector.
- Financial Recovery Signs: Revenue began to rebound in mid-2024, with first-quarter non-GAAP earnings growing 9.5% year-over-year, surpassing Wall Street expectations, indicating the company's potential for market recovery.
- Future Growth Expectations: Analysts project Danaher to grow earnings by 8% to 9% annually over the next three to five years, and with a current P/E ratio of 22, the stock appears attractive for long-term investment.
See More
Danaher Corporation Settles $172.5M Class Action Lawsuit
- Settlement Amount Confirmed: Danaher Corporation has agreed to pay $172.5 million to settle a class action lawsuit from investors who accused the company of misrepresenting demand for its testing and vaccine equipment as the COVID-19 pandemic waned, indicating a significant financial burden in managing legal risks.
- Lawsuit Background: Investors alleged that Danaher issued false and misleading statements regarding its bioprocessing business in 2022 and 2023, claiming sustainable demand for its products, which led to multiple declines in stock price, reflecting the company's missteps in market communication.
- Court Proceedings Update: The settlement agreement was filed with the US District Court for the District of Columbia on Wednesday, and if approved, it will become the largest securities class action settlement handled by that court since the relevant law took effect in 1996, highlighting the case's broad implications.
- Company's Position: While agreeing to the settlement, Danaher denied any wrongdoing, stating that this move will allow the company to avoid burdensome litigation and stay focused on addressing the world's most critical health challenges, reflecting its strategic emphasis on future business development.
See More
Thermo Fisher Exceeds Q1 Profit and Revenue Estimates
- Performance Beat: Thermo Fisher reported Q1 revenue of $11.01 billion, surpassing analysts' expectations of $10.85 billion, reflecting a 6% year-over-year growth driven by strong laboratory products and biopharma services.
- Segment Performance: Revenue from laboratory products and biopharma services rose approximately 7% to $6.04 billion, while analytical instruments remained flat at $1.72 billion, and specialty diagnostics saw a slight decline of 0.5% to $1.14 billion, indicating diverse market demand.
- Market Challenges: Despite strong overall performance, Thermo Fisher faces challenges from reduced funding for universities and research institutions under the Trump administration, which may impact future growth as smaller biotech firms remain cautious post-pandemic.
- Profitability Improvement: The company reported adjusted earnings per share of $5.44, exceeding the analysts' estimate of $5.24, indicating improvements in cost control and operational efficiency, which bolsters investor confidence.
See More
Danaher Corporation Prices €2.98 Billion Senior Notes Offering
- Financing Scale: Danaher Corporation's offering of senior notes is expected to yield approximately €2.98 billion in net proceeds after deducting underwriting discounts and estimated offering expenses, demonstrating the company's robust capital market capabilities.
- Use of Proceeds: The company intends to allocate a portion of the net proceeds to pay for the cash consideration and associated costs of acquiring Masimo Corporation, a strategic acquisition that will enhance Danaher's market position in the medical technology sector.
- Issuance Timeline: The offering is expected to close on April 29, 2026, subject to customary closing conditions, indicating the company's efficiency and planning in capital operations.
- Compliance Statement: The notes are not intended for retail investors, adhering to relevant EU and UK regulations, ensuring compliance throughout the issuance process and targeting professional investors.
See More
Danaher Corporation Prices Euro-Denominated Senior Notes Offering
- Offering Size: Danaher Corporation announced a total offering of €3 billion in senior notes, including €500 million of floating rate notes and €1 billion of 4% fixed rate notes, demonstrating the company's strong financing capability in the capital markets.
- Use of Proceeds: The estimated net proceeds of approximately €2.98 billion will primarily fund the cash consideration for the acquisition of Masimo Corporation and associated costs, indicating a proactive strategy to expand business and enhance market competitiveness.
- Market Response: The notes were priced close to par, reflecting investor confidence in Danaher's financial health, while also laying a solid foundation for future capital operations.
- Compliance Statement: The offering adheres to SEC registration statements, ensuring compliance with relevant laws and regulations, which underscores the company's commitment to compliance and transparency, thereby enhancing investor trust.
See More
